The Journal of Bone and Joint Surgery 79:326-33 (1997)
© 1997 The Journal of Bone and Joint Surgery, Inc.
Prevention of Thromboembolism with Use of Recombinant Hirudin. Results of a Double-Blind, Multicenter Trial Comparing the Efficacy of Desirudin (Revasc) with That of Unfractionated Heparin in Patients Having a Total Hip Replacement*
BENGT I. ERIKSSON, M.D., PH.D. , GÖTEBORG,
STEFFAN EKMAN, M.SC. PHARM , BASEL,
SIV LINDBRATT, D.D.S. , GÖTEBORG,
MARKUS BAUR, PH.D.,
DORIS BACH, M.SC., BASEL,
CARSTEN TØRHOLM, M.D., PH.D.¶, HELLERUP, DENMARK,
PETER KÄLEBO, M.D., PH.D., GÖTEBORG, SWEDEN and
PHILIPPE CLOSE, M.D., BASEL SWITZERLAND
Investigation performed at the Departments of Orthopedics and Radiology, University of Göteborg, Göteborg; Ciba-Geigy, Basel and Göteborg; and the Department of Orthopedics, Gentofte Hospital, Hellerup
Specific inhibition of thrombin is a new method for the prevention of postoperative deep-vein thrombosis. The objective of this multicenter, randomized, double-blind study was to compare the efficacy and safety of desirudin (Revasc, CGP 39393; fifteen milligrams two times a day) with that of unfractionated heparin (5000 international units three times a day) in patients having a primary elective total hip replacement. The medications were administered subcutaneously, starting preoperatively and continuing for eight to eleven days. The primary end point was a confirmed thromboembolic event during the treatment period. The presence of deep-vein thrombosis was evaluated with bilateral venograms, which were centrally assessed by two independent radiologists.
A total of 445 eligible patients were randomized: 220, to management with heparin, and 225, to management with desirudin. A per-protocol analysis of efficacy was performed for the 351 patients (79 per cent) for whom an adequate bilateral venogram had been made within eight to eleven days after the operation or who had had a proved thromboembolic event. The prevalence of confirmed deep-vein thrombosis was thirteen (7 per cent) of 174 patients who had received desirudin and forty-one (23 per cent) of 177 patients who had received heparin, a significant difference (p < 0.0001). The prevalence of proximal deep-vein thrombosis was also significantly reduced (p < 0.0001), by 79 per cent, in the group that had received desirudin (six [3 per cent] of 174 patients) compared with in the group that had received heparin (twenty-nine [16 per cent] of 177). There were no confirmed pulmonary embolisms or deaths during the period of prophylaxis. During a six-week follow-up period, pulmonary embolism was confirmed in four patients, all of whom had received heparin. There was no significant difference between the treatment groups with respect to bleeding variables or bleeding complications.
These data demonstrate that a fixed dose of fifteen milligrams of desirudin, started preoperatively and administered subcutaneously twice daily for at least eight days, provided effective, safe prevention of thromboembolic complications, with no specific requirements for laboratory monitoring, in patients who had a total hip replacement.
 CiteULike  Connotea  Del.icio.us  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Di Nisio, S. Middeldorp, and H. R. Buller
Direct Thrombin Inhibitors
N. Engl. J. Med.,
September 8, 2005;
353(10):
1028 - 1040.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hirsh, M. O'Donnell, and J. I. Weitz
New anticoagulants
Blood,
January 15, 2005;
105(2):
453 - 463.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I. Weitz, J. Hirsh, and M. M. Samama
New Anticoagulant Drugs: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest,
September 1, 2004;
126(3_suppl):
265S - 286S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Geerts, G. F. Pineo, J. A. Heit, D. Bergqvist, M. R. Lassen, C. W. Colwell, and J. G. Ray
Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest,
September 1, 2004;
126(3_suppl):
338S - 400S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Bates and J. I. Weitz
Emerging Anticoagulant Drugs
Arterioscler. Thromb. Vasc. Biol.,
September 1, 2003;
23(9):
1491 - 1500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Heit
The Potential Role of Direct Thrombin Inhibitors in the Prevention and Treatment of Venous Thromboembolism
Chest,
September 1, 2003;
124(3_suppl):
40S - 48S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Hyers
Management of Venous Thromboembolism: Past, Present, and Future
Arch Intern Med,
April 14, 2003;
163(7):
759 - 768.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Greinacher, P. Eichler, D. Albrecht, U. Strobel, B. Potzsch, and B. I. Eriksson
Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance
Blood,
April 1, 2003;
101(7):
2617 - 2619.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. W. Francis, B. L. Davidson, S. D. Berkowitz, P. A. Lotke, J. S. Ginsberg, J. R. Lieberman, A. K. Webster, J. P. Whipple, G. R. Peters, and C. W. Colwell Jr.
Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty: A Randomized, Double-Blind Trial
Ann Intern Med,
October 15, 2002;
137(8):
648 - 655.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Heit, C. W. Colwell, C. W. Francis, J. S. Ginsberg, S. D. Berkowitz, J. Whipple, G. Peters, and for the AstraZeneca Arthroplasty Study Group
Comparison of the Oral Direct Thrombin Inhibitor Ximelagatran With Enoxaparin as Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: A Phase 2 Dose-Finding Study
Arch Intern Med,
October 8, 2001;
161(18):
2215 - 2221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Geerts, J. A. Heit, G. P. Clagett, G. F. Pineo, C. W. Colwell, F. A. Anderson Jr., and H. B. Wheeler
Prevention of Venous Thromboembolism
Chest,
January 1, 2001;
119(1_suppl):
132S - 175S.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. B. Freedman, K. R. Brookenthal, R. H. Fitzgerald, S. Williams, and J. H. Lonner
A Meta-Analysis of Thromboembolic Prophylaxis Following Elective Total Hip Arthroplasty
J. Bone Joint Surg. Am.,
July 1, 2000;
82(7):
929 - 929.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. D. Hull and G. F. Pineo
Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism: Current Recommendations
Clinical and Applied Thrombosis/Hemostasis,
April 1, 1998;
4(2):
96 - 104.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Robb and B. I. Eriksson
Recombinant Hirudin Compared with Low-Molecular-Weight Heparin to Prevent Thromboembolic Complications after Total Hip Replacement
N. Engl. J. Med.,
March 26, 1998;
338(13):
920 - 921.
[Full Text]
|
|
|
|
|
|
|
B. I. Eriksson, P. Wille-Jorgensen, P. Kalebo, P. Mouret, N. Rosencher, P. Bosch, M. Baur, S. Ekman, D. Bach, S. Lindbratt, et al.
A Comparison of Recombinant Hirudin with a Low-Molecular-Weight Heparin to Prevent Thromboembolic Complications after Total Hip Replacement
N. Engl. J. Med.,
November 6, 1997;
337(19):
1329 - 1335.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Ewenstein
Antithrombotic Agents and Thromboembolic Disease
N. Engl. J. Med.,
November 6, 1997;
337(19):
1383 - 1384.
[Full Text]
|
|
|
|
